These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

217 related items for PubMed ID: 19335280

  • 1. The role of telavancin in the treatment of MRSA infections in hospital.
    Bassetti M, Mikulska M, Righi E, Nicolini L, Viscoli C.
    Expert Opin Investig Drugs; 2009 Apr; 18(4):521-9. PubMed ID: 19335280
    [Abstract] [Full Text] [Related]

  • 2. New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin.
    Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagacé-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA.
    Drugs; 2010 May 07; 70(7):859-86. PubMed ID: 20426497
    [Abstract] [Full Text] [Related]

  • 3. The role of telavancin in hospital-acquired pneumonia and ventilator-associated pneumonia.
    Sandrock CE, Shorr AF.
    Clin Infect Dis; 2015 Sep 15; 61 Suppl 2():S79-86. PubMed ID: 26316561
    [Abstract] [Full Text] [Related]

  • 4. Telavancin: a novel lipoglycopeptide for serious gram-positive infections.
    Laohavaleeson S, Kuti JL, Nicolau DP.
    Expert Opin Investig Drugs; 2007 Mar 15; 16(3):347-57. PubMed ID: 17302529
    [Abstract] [Full Text] [Related]

  • 5. Telavancin.
    Lyseng-Williamson KA, Blick SK.
    Drugs; 2009 Mar 15; 69(18):2607-20. PubMed ID: 19943710
    [Abstract] [Full Text] [Related]

  • 6. A comparative review of the lipoglycopeptides: oritavancin, dalbavancin, and telavancin.
    Guskey MT, Tsuji BT.
    Pharmacotherapy; 2010 Jan 15; 30(1):80-94. PubMed ID: 20030476
    [Abstract] [Full Text] [Related]

  • 7. Telavancin: a novel lipoglycopeptide antimicrobial agent.
    Attwood RJ, LaPlante KL.
    Am J Health Syst Pharm; 2007 Nov 15; 64(22):2335-48. PubMed ID: 17989443
    [Abstract] [Full Text] [Related]

  • 8. Telavancin: a new lipoglycopeptide for gram-positive infections.
    Smith WJ, Drew RH.
    Drugs Today (Barc); 2009 Mar 15; 45(3):159-73. PubMed ID: 19436839
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study.
    Stryjewski ME, Lentnek A, O'Riordan W, Pullman J, Tambyah PA, Miró JM, Fowler VG, Barriere SL, Kitt MM, Corey GR.
    BMC Infect Dis; 2014 May 23; 14():289. PubMed ID: 24884578
    [Abstract] [Full Text] [Related]

  • 12. Telavancin: a review of its use in patients with nosocomial pneumonia.
    Scott LJ.
    Drugs; 2013 Nov 23; 73(16):1829-39. PubMed ID: 24190596
    [Abstract] [Full Text] [Related]

  • 13. Telavancin for the treatment of hospital-acquired pneumonia: findings from the ATTAIN studies.
    Nannini EC, Corey GR, Stryjewski ME.
    Expert Rev Anti Infect Ther; 2012 Aug 23; 10(8):847-54. PubMed ID: 23030322
    [Abstract] [Full Text] [Related]

  • 14. Potential role for telavancin in bacteremic infections due to gram-positive pathogens: focus on Staphylococcus aureus.
    Corey GR, Rubinstein E, Stryjewski ME, Bassetti M, Barriere SL.
    Clin Infect Dis; 2015 Mar 01; 60(5):787-96. PubMed ID: 25472944
    [Abstract] [Full Text] [Related]

  • 15. ATLAS trials: efficacy and safety of telavancin compared with vancomycin for the treatment of skin infections.
    Barriere SL.
    Future Microbiol; 2010 Dec 01; 5(12):1765-73. PubMed ID: 21080861
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of telavancin in clinical trials: a systematic review and meta-analysis.
    Polyzos KA, Mavros MN, Vardakas KZ, Makris MC, Rafailidis PI, Falagas ME.
    PLoS One; 2012 Dec 01; 7(8):e41870. PubMed ID: 22916113
    [Abstract] [Full Text] [Related]

  • 18. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against gram-positive bacteria.
    Hegde SS, Reyes N, Wiens T, Vanasse N, Skinner R, McCullough J, Kaniga K, Pace J, Thomas R, Shaw JP, Obedencio G, Judice JK.
    Antimicrob Agents Chemother; 2004 Aug 01; 48(8):3043-50. PubMed ID: 15273119
    [Abstract] [Full Text] [Related]

  • 19. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria.
    Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, Fowler VG, Chu VH, Spencer E, Barriere SL, Kitt MM, Cabell CH, Corey GR, FAST Investigator Group.
    Clin Infect Dis; 2005 Jun 01; 40(11):1601-7. PubMed ID: 15889357
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.